Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient | GenomeWeb

By Turna Ray

As part of its Genetics for Generics program, Medco is planning a comparative effectiveness study of two competing blood-thinning drugs • Bristol-Myers Squibb's soon-to-be off-patent Plavix and Eli Lilly's newer, more expensive Effient • to assess whether it will be clinically useful and cost-effective to genetically test Plavix patients to establish their CYP2C19 status.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.